Drug intelligence / Profile preview

gutinib

Development stage: Preclinical
Lead developer: KeifeRx
Modality: Small Molecules
Administration: Oral

Overview

Gutinib is a novel, orally delivered small molecule tyrosine kinase inhibitor (TKI) being developed by KeifeRx, based on technology licensed from Georgetown University. It is designed to penetrate the blood-brain barrier and is intended for the treatment of neurodegenerative diseases. The drug's mechanism of action involves inducing autophagy, a cellular process that clears toxic proteins, and potentially reducing neuroinflammation and repairing vascular damage, thereby addressing the root causes of neurodegeneration. Gutinib is currently undergoing optimizing and IND-enabling studies.

Targets

DDR2 (Discoidin domain receptor tyrosine kinase 2)DDR1 (Discoidin domain receptor 1)

Beyond the preview

Go deeper on gutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gutinib.

Explore the full profile